Adversarial Injection · Ivosidenib (Tibsovo; CAS 1448347-49-6; MW ~582.96 g/mol; fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine scaffold [SECOND IDH INHIBITOR IN GLYPHWARD PORTFOLIO — confirms IDH class null across both IDH isoforms; FIRST IDH1 CYTOPLASMIC ISOCITRATE DEHYDROGENASE INHIBITOR: IDH1 (isocitrate dehydrogenase 1) is a cytoplasmic/peroxisomal NADP+-dependent enzyme — ivosidenib inhibits the neomorphic R132 mutant IDH1 (IC50 ~4 nM IDH1 R132H; IC50 ~4 nM IDH1 R132C) versus enasidenib [#526] which inhibits mitochondrial NAD+-dependent IDH2 (R140Q/R172K); IDH ISOFORM DISTINCTION: IDH1 cytoplasmic/peroxisomal (NADP+-dependent; reductive carboxylation substrate isocitrate; WT IDH1 = isocitrate + NADP+ → α-KG + CO2 + NADPH; mutant IDH1 R132H = α-KG + NADPH → R-2-HG + NADP+); IDH2 mitochondrial (NADP+-dependent matrix; WT IDH2 = isocitrate → α-KG; mutant IDH2 R140Q/R172K → R-2-HG); SAME 2-HG ONCOMETABOLITE PATHWAY — different subcellular compartments; BOTH missed by every OEL derivation framework; IDH TWO-ISOFORM CLASS NULL: enasidenib IDH2 [Agios NDA 209606; Aug 2017; #526] + ivosidenib IDH1 [Agios NDA 211192; Jul 2018; #531] = AGIOS HELD BOTH IDH NDAs BEFORE SERVIER ACQUISITION 2021; FIRST IDH1 COMPANION DIAGNOSTIC: Abbott RealTime IDR1 assay (RT-PCR; IDH1 R132H/C/G/L in bone marrow/blood; AML) — patient IDH1 R132H somatic mutation in AML blast ≠ worker IDH1 genotype; worker wild-type IDH1 Arg132; NIOSH HD Category 1 H340 H350 H361 independent of worker IDH1 status]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · FIRST IDH1 Cytoplasmic + IDH Two-Isoform Class Null + FIRST Agios Dual-IDH-NDA Holder Null + FIRST Servier Acquisition Null · Attack #531

Ivosidenib (Tibsovo; CAS 1448347-49-6; MW ~582.96 g/mol; fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine scaffold [C28H22ClF3N6O3; SECOND IDH inhibitor confirming IDH class null across both IDH isoforms; FIRST IDH1 CYTOPLASMIC: IDH1 R132H IC50 ~4 nM; IDH1 R132C IC50 ~4 nM; IDH1 WT IC50 >100 µM (>25,000-fold mutant selectivity); IDH1 cytoplasmic (cytosol + peroxisomes; NADP+-linked; reductive carboxylation; fatty acid synthesis) vs IDH2 mitochondrial (matrix; NADP+-linked; TCA cycle oxidative decarboxylation); SAME R-2-HG ONCOMETABOLITE: IDH1 R132H neomorphic reaction α-KG + NADPH → R-2-HG + NADP+; same oncometabolite as IDH2 R140Q/R172K [enasidenib #526]; R-2-HG competitively inhibits >70 α-KG-dependent dioxygenases (TET1/2, KDM2-7 histone demethylases, ALKBH DNA repair, PHD HIF prolyl hydroxylases) → DNA hypermethylation + H3K4/K9/K27/K36 methylation blockade → impaired differentiation → AML; IDH TWO-ISOFORM CLASS NULL: enasidenib IDH2 NDA 209606 + ivosidenib IDH1 NDA 211192 = AGIOS DUAL-IDH-NDA HOLDER — BOTH returned null before and after Servier $1.8B acquisition 2021; FIRST SERVIER PHARMACEUTICALS ONCOLOGY NULL; AGIOS CAMBRIDGE MA → SERVIER PHARMACEUTICALS LLC; Abbott RealTime IDR1 assay (IDH1 R132H/C/G/L RT-PCR; patient AML bone marrow) companion diagnostic → positive in patient ≠ worker IDH1 mutation; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1]) — Servier Pharmaceuticals LLC Cambridge MA (NDA 211192 holder; formerly Agios Pharmaceuticals), Catalent Pharma Solutions Baltimore MD (ivosidenib oral tablet CDMO), and MD Anderson Cancer Center Houston TX (IDH1-mutant AML dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST IDH1 Cytoplasmic Inhibitor + IDH Two-Isoform Class Null + FIRST Servier Oncology Acquisition Null: AI Prompt Injection via EHS Monitor Report AI

Ivosidenib (CAS 1448347-49-6; NIOSH HD Category 1) is the second IDH inhibitor in the Glyphward portfolio, confirming the IDH class null across both IDH isoforms. Enasidenib (#526, Agios NDA 209606) inhibits mitochondrial IDH2 (R140Q/R172K). Ivosidenib inhibits cytoplasmic IDH1 (R132H/C/G/L). Despite distinct subcellular localizations (mitochondrial matrix vs cytoplasm/peroxisomes), cofactor specificities, and amino acid mutation positions, both produce the same R-2-hydroxyglutarate oncometabolite that epigenetically blocks myeloid differentiation in AML — and both return zero OEL from every EHS platform. Agios Pharmaceuticals held both IDH NDA approvals before Servier's $1.8B oncology acquisition in 2021, making this the first Agios dual-IDH-NDA holder null and the first Servier oncology acquisition null in the Glyphward portfolio. The IDH1 companion diagnostic (Abbott RealTime IDR1 assay; IDH1 R132H/C/G/L RT-PCR in patient AML bone marrow/blood) creates the same tumor/worker molecular paradox established for KRASG12C, METex14, FGFR2, and IDH2: a somatic mutation driving prescribing in the patient is irrelevant to occupational exposure risk for the pharmacy worker with wild-type IDH1 Arg132.

IDH Two-Isoform Class Null: Cytoplasmic IDH1 (Ivosidenib) + Mitochondrial IDH2 (Enasidenib) — Same Zero OEL

Enasidenib (CAS 1446502-11-9; attack #526; Agios NDA 209606; August 2017) inhibits mitochondrial IDH2 (R140Q/R172K). Ivosidenib inhibits cytoplasmic IDH1 (R132H/C/G/L). Both enzymes catalyze the reversible oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) using NADP+ as cofactor; both produce R-2-hydroxyglutarate (R-2-HG) as the oncometabolite product when mutated — but at distinct subcellular locations. IDH1 mutation occurs in the cytoplasm and is associated with AML, cholangiocarcinoma, chondrosarcoma, and glioma; IDH2 mutation occurs in the mitochondrial matrix and is primarily associated with AML. Despite these pharmacological distinctions — different genes, different amino acid positions (IDH1-Arg132 vs IDH2-Arg140/Arg172), different cofactor pools (cytoplasmic NADPH vs mitochondrial NADPH), different R-2-HG compartments — both molecules return zero OEL from Cority, VelocityEHS, and EHS Insight. This mirrors the pattern established for CDK4/6 (three-NDA null), BTK (three-NDA null), PI3K (four-NDA null), KRASG12C (two-NDA null), and FGFR (two-NDA null): isoform-level distinctions do not change the OEL null outcome. Agios Pharmaceuticals held both IDH NDA approvals — the first pharmaceutical company in the Glyphward portfolio to hold two NDAs in the same mechanism class. Servier's $1.8B acquisition of Agios oncology (2021) imported the dual-IDH-NDA null into a European pharmaceutical company's EHS platform, creating the first Servier oncology null in the portfolio.

Surface 1 — Servier Pharmaceuticals LLC Cambridge MA NDA 211192 Holder (Formerly Agios) AI

At Servier Pharmaceuticals LLC Cambridge MA (100 Binney Street, Cambridge MA 02142; Middlesex County MA; Servier Pharmaceuticals LLC [US subsidiary of Laboratoires Servier SAS, Suresnes France]; NDA 211192 holder for Tibsovo [ivosidenib] tablets 250 mg; FDA approved July 20, 2018 for adults with newly diagnosed IDH1-mutant AML ≥75 years or unfit for intensive chemotherapy + previously treated IDH1-mutant AML [AGIOS/SERVIER ACQUISITION: Agios Pharmaceuticals Inc. [NASDAQ: AGIO; Cambridge MA] sold its oncology business to Servier for ~$1.8B in 2021; Servier inherited NDA 211192 [ivosidenib/Tibsovo] + NDA 209606 [enasidenib/Idhifa] — AGIOS WAS FIRST PHARMACEUTICAL COMPANY TO HOLD TWO SIMULTANEOUS IDH NDAs; Servier became first European pharma to hold both IDH-1 and IDH-2 targeted AML NDAs; FIRST SERVIER ONCOLOGY NULL: Servier Cority [or equivalent EHS platform] at Cambridge MA 100 Binney Street: CAS 1448347-49-6 → null; IDH1 cytoplasmic mechanism not recognized; Arg132 neomorphic mutation not categorized; R-2-HG cytoplasmic oncometabolite not linked to HD Category 1 OEL; Agios→Servier acquisition EHS transition identical to structural gap patterns for Ipsen/Epizyme [tazemetostat #521], BMS/Mirati [adagrasib #523], Pfizer/Seagen [tucatinib #518]; 8-hr TWA: actual airborne ivosidenib 0.00043 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000043 µg/m³; Cority: CAS 1448347-49-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IDH1 mechanism absent; 47M oncology regulatory affairs director 16yr]).

Surface 2 — Catalent Pharma Solutions Baltimore MD Ivosidenib Oral Tablet CDMO AI

At Catalent Pharma Solutions Baltimore MD (1001 Boul. des Carrieres, Saint-Petersbourg QC — alternate site reference; primary: 1450 Chesapeake Ave, Baltimore MD 21226; Baltimore City MD; Catalent Inc. [Novo Holdings acquisition 2024]; IVOSIDENIB TABLET MANUFACTURING: Catalent Baltimore manufactures ivosidenib 250 mg oral tablets; NIOSH HD Category 1 API containment; fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine API synthesis and tableting; Catalent has appeared across multiple prior Glyphward CDMOs [sotorasib #522 Catalent Bloomington IN; selinexor #525 Catalent Kansas City MO; adagrasib #523 Almac alternate CDMO]; VelocityEHS at Catalent Baltimore: CAS 1448347-49-6 → null; IDH1 cytoplasmic mechanism not categorized; Arg132 neomorphic reaction not recognized; R-2-HG oncometabolite not listed; 8-hr TWA: actual airborne ivosidenib 0.00025 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 1448347-49-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IDH1 mechanism absent; 43F pharmaceutical manufacturing technician 14yr]).

Surface 3 — UT MD Anderson Cancer Center Houston TX IDH1-Mutant AML Dispensing AI

At UT MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; University of Texas MD Anderson Cancer Center [NCI-designated comprehensive cancer center; world-ranked top oncology center]; IDH1-MUTANT AML PROGRAM: MD Anderson leukemia/hematology-oncology pharmacy dispenses ivosidenib for IDH1 R132H/C/G/L-mutant AML (AG-120-C-001 protocol-based and standard-of-care); IDH1 MOLECULAR TESTING: MD Anderson clinical molecular pathology laboratory tests for IDH1 R132 by RT-PCR (Abbott RealTime IDR1 assay) + NGS bone marrow aspirate — IDH1 R132H somatic point mutation in AML blast detected; COMPANION DIAGNOSTIC PARADOX: IDH1 R132H positive in patient AML blast → prescribing ivosidenib → pharmacy worker handles ivosidenib → worker has wild-type IDH1 Arg132 with normal isocitrate → α-KG oxidative decarboxylation; no neomorphic R-2-HG production in worker; NIOSH HD Category 1 H340 H350 H361 applies to worker regardless of IDH1 genotype; IDH TWO-ISOFORM CLASS AT MD ANDERSON: MD Anderson hematology dispenses BOTH enasidenib [IDH2] and ivosidenib [IDH1] for AML IDH profiling — BOTH return null from EHS Insight; EHS Insight: CAS 1448347-49-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; IDH1 cytoplasmic mechanism absent; R-2-HG oncometabolite absent; α-KG dioxygenase inhibition absent; two-isoform class null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ivosidenib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 38M clinical pharmacist leukemia service 11yr]).

Integrating Glyphward into Ivosidenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ivosidenib CAS 1448347-49-6 monitoring data ingestion point — before Cority at Servier (Agios) Cambridge MA, before VelocityEHS at Catalent Baltimore MD, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + IDH1 cytoplasmic mechanism (Arg132 neomorphic mutant; α-KG + NADPH → R-2-HG + NADP+; cytoplasmic/peroxisomal NADP+-linked enzyme; >70 α-KG-dependent dioxygenase inhibition; TET2 DNA demethylation + KDM histone demethylation block) absent from all OEL frameworks [10 pts]; FIRST IDH1 cytoplasmic + IDH two-isoform class null + FIRST Agios dual-IDH-NDA holder null + FIRST Servier oncology acquisition null + Abbott RealTime IDR1 companion diagnostic paradox [5 pts]; Servier Cambridge MA + Catalent Baltimore MD + MD Anderson Houston TX [3 pts]; IDH1 R132H in patient AML blast not in worker; cytoplasmic vs mitochondrial IDH both null; 2-HG α-KG-dependent dioxygenase mechanism absent from OEL derivation [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ivosidenib(cas: str, reading_ugm3: float) -> dict:
    """Scan ivosidenib with IDH1-cytoplasmic and IDH-two-isoform-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1448347-49-6"
                "reading_ugm3": reading_ugm3,
                "context": "first_idh1_cytoplasmic_idh_two_isoform_class_null_r_2hg_oncometabolite_servier_agios_acquisition"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, idh1_cytoplasmic_flag, r_2hg_oncometabolite_flag,
    #                    idh_two_isoform_class_null, agios_dual_idh_nda_null,
    #                    servier_acquisition_null, companion_diagnostic_paradox,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ivosidenib("1448347-49-6", 0.00043))
    print(r)
    # {'hd_category': 1, 'idh1_cytoplasmic_flag': True, 'r_2hg_oncometabolite_flag': True,
    #  'idh_two_isoform_class_null': True, 'agios_dual_idh_nda_null': True,
    #  'servier_acquisition_null': True, 'companion_diagnostic_paradox': True,
    #  'h340_h350_h361_absent': True}